Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping (EARS)

NCT04928690 is registered in ClinicalTrials.gov with Novoic Limited as lead sponsor.

NCT NCT04928690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04928690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping (EARS)
Lead sponsor
Novoic Limited
Phase
Observational
Overall status
Unknown status
Start date
June 20, 2021
Completion date
August 30, 2022
Enrollment
140 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, alzheimer's disease (incl subtypes), mild cognitive impairment